SETTING: Rates of multidrug-resistant tuberculosis (MDR-TB) are currently as high as 7.7% in retreatment cases in KwaZulu-Natal, South Africa. MDR-TB prevalence is known to be high in patients categorized as treatment failures. Recent reports have questioned the effectiveness of the World Health Organization (WHO) Category II regimen in retreatment TB cases. OBJECTIVE: To determine whether treatment category predicts susceptibility patterns and outcomes in a hospitalized population of retreatment TB cases. DESIGN: Retrospective cohort of 197 pulmonary retreatment cases. RESULTS: Retreatment cases treated with the standard retreatment regimen had a high in-hospital mortality (19.8%), or poor outcome (26.4%) and a high rate of MDR-TB (16.2%). The 'treatment failure' category predicted resistance, with 57.1% of patients exhibiting any resistance compared to other treatment categories (P = 0.02); 53.8% of patients with any resistance experienced poor outcomes, compared to 16.6% of pan-susceptible cases (P = 0.02). There was a trend towards poor outcome in the treatment failure category (42.9%, P = 0.13). CONCLUSION: The retreatment category 'treatment failure' is associated with a high prevalence of resistance in an area of high human immunodeficiency virus (HIV) prevalence. The 'treatment failure' category should be used to identify patients who may benefit from alternative regimens using directed, intensified therapy or second-line agents instead of the current standard retreatment regimen.
SETTING: Rates of multidrug-resistant tuberculosis (MDR-TB) are currently as high as 7.7% in retreatment cases in KwaZulu-Natal, South Africa. MDR-TB prevalence is known to be high in patients categorized as treatment failures. Recent reports have questioned the effectiveness of the World Health Organization (WHO) Category II regimen in retreatment TB cases. OBJECTIVE: To determine whether treatment category predicts susceptibility patterns and outcomes in a hospitalized population of retreatment TB cases. DESIGN: Retrospective cohort of 197 pulmonary retreatment cases. RESULTS: Retreatment cases treated with the standard retreatment regimen had a high in-hospital mortality (19.8%), or poor outcome (26.4%) and a high rate of MDR-TB (16.2%). The 'treatment failure' category predicted resistance, with 57.1% of patients exhibiting any resistance compared to other treatment categories (P = 0.02); 53.8% of patients with any resistance experienced poor outcomes, compared to 16.6% of pan-susceptible cases (P = 0.02). There was a trend towards poor outcome in the treatment failure category (42.9%, P = 0.13). CONCLUSION: The retreatment category 'treatment failure' is associated with a high prevalence of resistance in an area of high human immunodeficiency virus (HIV) prevalence. The 'treatment failure' category should be used to identify patients who may benefit from alternative regimens using directed, intensified therapy or second-line agents instead of the current standard retreatment regimen.
Authors: J McGreevy; M A Jean Juste; P Severe; S Collins; S Koenig; J W Pape; D W Fitzgerald Journal: Int J Tuberc Lung Dis Date: 2012-04-09 Impact factor: 2.373
Authors: Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa Journal: PLoS Med Date: 2011-03-15 Impact factor: 11.069
Authors: Jason R Andrews; N Sarita Shah; Darren Weissman; Anthony P Moll; Gerald Friedland; Neel R Gandhi Journal: PLoS One Date: 2010-12-29 Impact factor: 3.240
Authors: Dickens O Onyango; Courtney M Yuen; Kevin P Cain; Faith Ngari; Enos O Masini; Martien W Borgdorff Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240
Authors: André N H Bulabula; Jenna A Nelson; Eric M Musafiri; Rhoderick Machekano; Nadia A Sam-Agudu; Andreas H Diacon; Maunank Shah; Jacob Creswell; Grant Theron; Robin M Warren; Karen R Jacobson; Jean-Paul Chirambiza; Dieudonné Kalumuna; Bertin C Bisimwa; Patrick D M C Katoto; Michel K Kaswa; Freddy M Birembano; Liliane Kitete; Martin P Grobusch; Zacharie M Kashongwe; Jean B Nachega Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Michel Kayomo Kaswa; Serge Bisuta; Georges Kabuya; Octavie Lunguya; André Ndongosieme; Jean Jacques Muyembe; Armand Van Deun; Marleen Boelaert Journal: PLoS One Date: 2014-04-14 Impact factor: 3.240